Protective effect of ellagic acid and pumpkin seed oil against methotrexate-induced small intestine damage in rats
IR@NISCAIR: CSIR-NISCAIR, New Delhi - ONLINE PERIODICALS REPOSITORY (NOPR)
View Archive Info| Field | Value | |
| Title |
Protective effect of ellagic acid and pumpkin seed oil against methotrexate-induced small intestine damage in rats
|
|
| Creator |
El-Boghdady, Noha A
|
|
| Subject |
Methotrexate
Oxidative stress Ellagic acid Pumpkin seed oil Purine catabolizing enzymes <span style="font-size:11.0pt;mso-bidi-font-size: 10.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"; mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" lang="EN-GB">Prostaglandin E<sub>2</sub></span> |
|
| Description |
380-387
<span style="font-size:11.0pt;mso-bidi-font-size: 10.0pt;font-family:" times="" new="" roman","serif";mso-fareast-font-family:"times="" roman";="" mso-ansi-language:en-gb;mso-fareast-language:en-us;mso-bidi-language:ar-sa"="" lang="EN-GB">Gastrointestinal toxicity is one of the most serious side effects in the methotrexate (MTX) treatment. This study was designed to investigate whether ellagic acid (EA) and/or pumpkin seed oil (PSO) had a protective effect on MTX-induced small intestine damage. Forty albino rats were randomized into five groups of 8 rats each. Group <span style="font-size:11.0pt;mso-bidi-font-size:10.0pt; font-family:Symbol;mso-ascii-font-family:" times="" new="" roman";mso-fareast-font-family:="" "times="" roman";mso-hansi-font-family:"times="" roman";mso-bidi-font-family:="" roman";mso-ansi-language:en-gb;mso-fareast-language:en-us;="" mso-bidi-language:ar-sa;mso-char-type:symbol;mso-symbol-font-family:symbol"="" lang="EN-GB">I<span style="font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:" times="" new="" roman","serif";="" mso-fareast-font-family:"times="" roman";mso-ansi-language:en-gb;mso-fareast-language:="" en-us;mso-bidi-language:ar-sa"="" lang="EN-GB"> served as a normal control group. In Group <span style="font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol; mso-ascii-font-family:" times="" new="" roman";mso-fareast-font-family:"times="" roman";="" mso-hansi-font-family:"times="" roman";mso-bidi-font-family:"times="" mso-ansi-language:en-gb;mso-fareast-language:en-us;mso-bidi-language:ar-sa;="" mso-char-type:symbol;mso-symbol-font-family:symbol"="" lang="EN-GB">II<span style="font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:" times="" new="" roman","serif";="" mso-fareast-font-family:"times="" roman";mso-ansi-language:en-gb;mso-fareast-language:="" en-us;mso-bidi-language:ar-sa"="" lang="EN-GB">, MTX was administered as a single dose (20 mg/kg) intraperitoneally. Groups <span style="font-size:11.0pt; mso-bidi-font-size:10.0pt;font-family:Symbol;mso-ascii-font-family:" times="" new="" roman";="" mso-fareast-font-family:"times="" roman";mso-hansi-font-family:"times="" mso-bidi-font-family:"times="" roman";mso-ansi-language:en-gb;mso-fareast-language:="" en-us;mso-bidi-language:ar-sa;mso-char-type:symbol;mso-symbol-font-family:symbol"="" lang="EN-GB">III<span style="font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:" times="" new="" roman","serif";="" mso-fareast-font-family:"times="" roman";mso-ansi-language:en-gb;mso-fareast-language:="" en-us;mso-bidi-language:ar-sa"="" lang="EN-GB">, <span style="font-size:11.0pt; mso-bidi-font-size:10.0pt;font-family:Symbol;mso-ascii-font-family:" times="" new="" roman";="" mso-fareast-font-family:"times="" roman";mso-hansi-font-family:"times="" mso-bidi-font-family:"times="" roman";mso-ansi-language:en-gb;mso-fareast-language:="" en-us;mso-bidi-language:ar-sa;mso-char-type:symbol;mso-symbol-font-family:symbol"="" lang="EN-GB">I<span style="font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:" times="" new="" roman","serif";="" mso-fareast-font-family:"times="" roman";mso-ansi-language:en-gb;mso-fareast-language:="" en-us;mso-bidi-language:ar-sa"="" lang="EN-GB">V and V were pre-treated respectively with either PSO (40 mg/kg), EA (10 mg/kg) or 0.2% DMSO (vehicle control) orally every day by gavage for 5 days and then they received MTX. All animals were sacrificed 5 days after the intraperitoneal injection of MTX for histopathological examination, estimation of serum prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) level, assay of tissue malondialdehyde (MDA), reduced glutathione (GSH) and nitric oxide (NO) levels and myloperoxidase (MPO), xanthine oxidase (XO) and adenosine deaminase (AD) activities. Administration of EA and/or PSO decreased the intestinal damage, PGE<sub>2</sub>, MDA and NO levels and MPO, XO and AD activities and increased GSH level. These results suggest that EA and PSO protect the small intestine of rats from MTX-induced damage through their antioxidant and anti-inflammatory effects and thus have potential as a promising drug in the prevention of undesired side effects of MTX.</span></span></span></span></span></span></span></span></span> |
|
| Date |
2011-12-23T10:29:17Z
2011-12-23T10:29:17Z 2011-12 |
|
| Type |
Article
|
|
| Identifier |
0975-0959 (Online); 0301-1208 (Print)
http://hdl.handle.net/123456789/13252 |
|
| Language |
en_US
|
|
| Rights |
<img src='http://nopr.niscair.res.in/image/cc-license-sml.png'> <a href='http://creativecommons.org/licenses/by-nc-nd/2.5/in' target='_blank'>CC Attribution-Noncommercial-No Derivative Works 2.5 India</a>
|
|
| Publisher |
NISCAIR-CSIR, India
|
|
| Source |
IJBB Vol.48(6) [December 2011]
|
|